{
  "pmcid": "12483610",
  "sha256": "c8e71e163282d4ee1c83010436126ad40774d257f05287be32b739c53b1c293d",
  "timestamp_utc": "2025-11-09T23:40:51.360478+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.085201646090535,
    "reading_ease": 22.93274074074074,
    "word_count": 243
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Complement System Modulation in Lung Transplantation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised controlled trial included adults eligible for lung transplantation"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at a tertiary care center, this randomised controlled trial included adults eligible for lung transplantation."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either a complement inhibitor or standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "To determine the effect of complement inhibition on lung transplant outcomes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of primary graft dysfunction (PGD) within 72 hours post-transplant."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, 100 to the intervention and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 in the intervention group and 97 in the control group, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group demonstrated a significant reduction in PGD incidence (mean difference = 15%, 95% CI 5% to 25%; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}